QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ELAN

QT72Elanco Animal Health Incorporated
NYSE·Healthcare·Drug Manufacturers - Specialty & Generic·USA
Latest market price
24.22
+0.83+3.55%
OverviewShort InterestFilings
ELANQT72Elanco Animal Health Incorporated·NYSE
OverviewShort InterestFilings
24.22+3.55%
TA
Loading chart...
Screen all →
TAK+1.36%$15.63HLN+1.01%$8.96TEVA-3.32%$31.48VTRS-2.29%$15.37RDY+1.06%$13.29RGC-18.96%$12.01LNTH+0.65%$103.86AMRX-0.43%$16.21
Snapshot
Index-P/E-EPS (ttm)-0.49
Insider Own1.13%
Shs Outstand499.45M
Perf Week0.71%
Market Cap11.68BForward P/E20.40EPS next Y1.19Insider Trans0.00%Shs Float-Perf Month22.32%
Enterprise Value15.25BPEG0.30EPS next Q0.28Inst Own-Short Float-Perf Quarter-3.58%
Income-242988216.00P/S2.39EPS this Y315.97%Inst Trans-Short Ratio-Perf Half Y7.69%
Sales4.89BP/B1.79EPS next Y12.17%ROA-1.83%Short Interest-Perf YTD7.03%
Book/sh13.01P/C20.18EPS next 5Y9.74%ROE-3.64%52W High27.72 -12.63%Perf Year77.96%
Cash/sh0.86P/FCF37.09EPS past 3/5Y-ROIC3.77%52W Low13.16 84.04%Perf 3Y-
Dividend Est.-EV/EBITDA19.95Sales past 3/5Y2.25% 7.57%Gross Margin49.44%Volatility2.58% 3.15%Perf 5Y-
Dividend TTM-EV/Sales3.12EPS Y/Y TTM44.12%Oper. Margin8.95%ATR (14)1.10Perf 10Y-
Dividend Ex-Date-Quick Ratio1.12Sales Y/Y TTM10.23%Profit Margin-4.95%RSI (14)54.91Recom2.20
Dividend Gr. 3/5Y-Current Ratio2.16EPS Q/Q8.11%SMA202.41%Beta1.53Target Price28.40
Payout0.00%Debt/Eq0.61Sales Q/Q14.92%SMA505.42%Rel Volume1.68Prev Close23.39
Employees9,000LT Debt/Eq0.60EarningsAug 06SMA2007.09%Avg Volume6.11MPrice24.22
IPO DateSep 20, 2018Option/ShortYes / YesEPS/Sales Surpr.15.74% 7.36%Net Debt/EBITDA4.66Volume10,241,797Change3.55%
Analyst Ratings
DateActionAnalystRatingTarget
May-15-26ReiteratedMorgan StanleyEqual Weight$24 → $23
Feb-25-26ReiteratedKeybancOverweight$27 → $29
Feb-24-26ReiteratedLeerink PartnersOutperform$18 → $30
Jan-29-26ReiteratedUBSBuy$27 → $30
Jan-22-26UpgradePiper SandlerNeutral → Overweight$12 → $30
Dec-18-25ReiteratedMorgan StanleyEqual Weight$37 → $22
Dec-08-25InitiatedBarclaysOverweight$22 → $30
Nov-20-25InitiatedKeyBancOverweight$27
Nov-19-25ReiteratedArgus Research$25
Nov-05-25ReiteratedStifel Nicolaus$23 → $27
Latest News
Jun-18-26
Jun-18-2611:26AM
Elanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal HealthYahoo
Jun-16-26
Jun-16-2612:09PM
1 Profitable Stock to Target This Week and 2 We AvoidYahoo
Jun-15-26
Jun-15-2612:47PM
Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for DogsYahoo
08:49AM
Elanco Animal Health Receives USDA Approval Of Its TruCan Ultra Lyme-L4 Combination VaccineBenzinga
Jun-12-26
Jun-12-2609:50AM
2 Cash-Producing Stocks on Our Buy List and 1 That UnderwhelmYahoo
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue4,8934,7154,439
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A2,4742,6652,530
Gross Profit2,4192,0501,909
Selling, General and Administrative Excl. Other1,4701,4301,314
Research and Development371368344
Other Operating Expense
14000
Operating Income438252251
Interest Expense270220339
Unusual Expense
———
Non-Operating Income (Expense)365256-576
Net Income Before Taxes-197-224488
Income Taxes458150
Consolidated Net Income-242-232338
Net Income From Continuing Operations-242-232338
Net Income-242-232338
EPS (Recurring)-0.50-0.470.68
EPS (Basic, Before Extraordinaries)-0.50-0.470.68
EPS (Diluted)-0.49-0.470.68
EBITDA7646761,489
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio2.472.38—
Gross Margin49.4443.4843.01
Operating Margin8.955.345.65
Net Margin-4.95-4.927.61
Shares Outstanding498496494
Market Capitalization12,06211,224—
Operating Lease Expense
———
Insider Trading Volume
$31.26$28.34$25.41$22.48$19.56● Close Price0.00K234.48K468.95K703.43K937.91KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Modi Rajeev A.SEE REMARKSMay 15 '26Buy20.354,91199,939160,812May 19 12:00 AM
Simmons Jeffrey NPRESIDENT, CEO AND DIRECTORMay 15 '26Buy20.094,97199,843171,971May 19 12:00 AM
Kurzius Lawrence ErikDirectorDec 12 '25Buy21.3010,000213,000131,773Dec 16 12:00 AM
Modi Rajeev A.SEE REMARKSDec 11 '25Buy21.334,50095,985123,082Dec 15 12:00 AM
VanHimbergen Robert MEVP and CFODec 11 '25Buy21.646,950150,426124,233Dec 15 12:00 AM
Simmons Jeffrey NPRESIDENT, CEO AND DIRECTORDec 11 '25Buy21.7522,000478,496167,000Dec 15 12:00 AM
Kurzius Lawrence ErikDirectorMar 11 '25Buy10.2010,000102,000111,459Mar 11 12:00 AM
Kurzius Lawrence ErikDirectorMar 07 '25Buy10.9010,000109,000101,459Mar 11 12:00 AM
HOOVER R DAVIDDirectorMar 05 '25Buy10.9025,000272,558210,000Mar 07 12:00 AM
Harrington Michael JDirectorAug 22 '24Buy14.853,50051,97481,094Aug 26 12:00 AM
Simmons Jeffrey NPRESIDENT, CEO AND DIRECTORAug 12 '24Buy13.01100,0001,300,610145,000Aug 13 12:00 AM
DOYLE WILLIAM FDirectorMay 21 '24Buy16.9815,000254,70076,330May 23 12:00 AM
DOYLE WILLIAM FDirectorMar 08 '24Buy16.3015,000244,50061,330Mar 12 12:00 AM
Harrington Michael JDirectorMar 08 '24Buy16.293,10050,49477,594Mar 12 12:00 AM
HOOVER R DAVIDDirectorMar 06 '24Buy16.1420,000322,808185,000Mar 08 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR